Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

PITTSBURGH, July 21, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. The manuscript, titled Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Clinical Trial of the Alzheimer's Disease Drug Candidate, CT1812, was published in the peer-reviewed journal Alzheimer's & Dementia: Translational Research & Clinical Interventions. SEQUEL was a single-site study that investigated the effect of zervimesine on synaptic function using quantitative electroencephalography (qEEG), a noninvasive technique to measure electrical activity of the brain.

Read more at globenewswire.com